Title:
【発明の名称】抗アレルギー治療に有効な化合物
Document Type and Number:
Japanese Patent JPH09505563
Kind Code:
A
Abstract:
Pharmaceutically acceptable compounds of less than 1200 MW for use in the treatment of IgE-mediated allergies comprising a first negatively charged atom or group and a second negatively charged atom or group, separated by a spacing group effective conformationally to position said negatively charged atoms or groups so that they will neutralize the lysine residues of the amino acid sequence Lys Thr Lys at positions 497-499 of the C ELEMENT 4 constant domain of cell-bound human IgE, but excluding any compounds already known for this purpose such as DSCG and nedocromil sodium and toxic compounds. In a second aspect, the present invention provides peptides of formula (I) (in which the left-hand side represents the N-terminus and the right-hand side the C terminus): R<1>m Xaa<1> Sp Xaa<2> R<2>n wherein: R<1> represents a residue of an amino acid or of a sequence of two or three amino acids, which may be the same or different; R<2> represents a residue of an amino acid or of a sequence of two or three amino acids, which may be the same or different; (but preferably any amino acid residue of R<1> or R<2> adjacent to an Xaa residue is neither positively nor negatively charged); Xaa<1> represents a residue of a negatively charged amino acid, preferably Glu; Sp represents a spacing residue, preferably of a non-charged amino acid, preferably Pro, or of a non-charged dipeptide, which provides the spacing required for the negatively charged groups of the Xaa residues to be sufficiently proximal to the lysine residues of the amino acid sequence Lys Thr Lys at positions 497-499 of the C ELEMENT 4 constant domain of cell-bound human IgE to neutralise them; Xaa<2> represents a residue of a negatively charged amino acid, preferably Glu; and m and n denote the number of amino acids in R<1> and R<2> respectively and each of m and n independently is 0, 1, 2 or 3, and the sum of m plus n is from 0 to 3; and their terminal functional derivatives; both per se and for use in the treatment of IgE-mediated allergies.
Inventors:
Liuin Ian Victor
Stanworth Dennis Raymond
Stanworth Dennis Raymond
Application Number:
JP51147395A
Publication Date:
June 03, 1997
Filing Date:
October 11, 1994
Export Citation:
Assignee:
Peptide Therapeutics Limited
International Classes:
G01N33/53; A61K38/00; A61K49/00; A61P37/08; A61P43/00; C07K5/093; C07K5/103; C07K5/113; C07K7/06; (IPC1-7): C07K5/093; A61K38/00; A61K49/00; C07K5/103; C07K5/113; C07K7/06; G01N33/53
Attorney, Agent or Firm:
Minoru Nakamura (6 outside)